These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 23227588)

  • 1. [Personalized treatment in non-small cell lung cancer].
    Campos-Parra AD; Cruz-Rico G; Arrieta O
    Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
    Shi YK
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):398-400. PubMed ID: 22883466
    [No Abstract]   [Full Text] [Related]  

  • 3. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
    Girard N
    Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted treatment tested as potential cancer cure.
    Hayden EC
    Nature; 2011 Nov; 479(7373):281. PubMed ID: 22094668
    [No Abstract]   [Full Text] [Related]  

  • 5. Gefitinib in the treatment of advanced non-small-cell lung cancer.
    Reck M
    Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [CRAF, a key player in lung adenocarcinomas induced by K-Ras oncogene].
    Francoz S; Dubus P
    Med Sci (Paris); 2011 Oct; 27(10):820-2. PubMed ID: 22027418
    [No Abstract]   [Full Text] [Related]  

  • 7. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 10. More than just an oncogene translocation and a kinase inhibitor: Kevin's story.
    Costa DB
    J Clin Oncol; 2012 Jan; 30(1):110-2. PubMed ID: 22067391
    [No Abstract]   [Full Text] [Related]  

  • 11. Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
    Santarpia M; Altavilla G; Salazar MF; Magri I; Pettineo G; Benecchi S; Rosell R
    Expert Rev Respir Med; 2011 Jun; 5(3):413-24. PubMed ID: 21702662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
    Friedrich MJ
    J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
    [No Abstract]   [Full Text] [Related]  

  • 13. Directed therapies in lung cancer: new hope?
    Parente Lamelas I; Abal Arca J; Fírvida Pérez JL
    Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New era in cancer therapy. Gefitinib: small molecule--strong action].
    Arnheim K
    MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
    [No Abstract]   [Full Text] [Related]  

  • 15. [Is it possible to treat bronchial carcinoma without chemotherapy?].
    Pujol JL
    Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S23-10S26. PubMed ID: 17127957
    [No Abstract]   [Full Text] [Related]  

  • 16. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
    [No Abstract]   [Full Text] [Related]  

  • 17. Personalized medicine for non-small-cell lung cancer.
    Mok TS; Zhou Q; Leung L; Loong HH
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
    Reddy GK
    Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
    [No Abstract]   [Full Text] [Related]  

  • 19. Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.
    Hirai F; Takenoyama M; Taguchi K; Toyozawa R; Inamasu E; Toyokawa G; Yoshida T; Shiraishi Y; Takenaka T; Yamaguchi M; Ushijima C; Seto T; Takeo S; Ichinose Y
    J Thorac Oncol; 2014 May; 9(5):e37-9. PubMed ID: 24722163
    [No Abstract]   [Full Text] [Related]  

  • 20. ALK, lung cancer, and personalized therapy: portent of the future?
    Garber K
    J Natl Cancer Inst; 2010 May; 102(10):672-5. PubMed ID: 20460631
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.